UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER - Endpoints News https://t.co/CJvIv6x9zY
— IDRO (@IDROOhio) May 23, 2019
from Twitter https://twitter.com/IDROOhio
May 23, 2019 at 05:42AM
Thursday, May 23, 2019
UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER - Endpoints News https://t.co/CJvIv6x9zY
from Twitter https://twitter.com/IDROOhio
May 23, 2019 at 05:42AM
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment